24/7 Market News Snapshot 31 March, 2025 – Apollomics Inc. Class A Ordinary Shares (NASDAQ:APLM)

March 31, 2025

DENVER, Colo., 31 March, 2025 (247marketnews.com) – (NASDAQ:APLM) are discussed in this article.
Apollomics Inc. has experienced substantial growth today, beginning trading at $7.51 and reaching a peak of $8.765, a notable 15.18% increase from a prior closing price of $7.61. This surge reflects strong buying interest, with trading volume hitting 502.81K shares, indicative of heightened market activity and investor confidence. Market analysts are closely watching key price levels, with resistance identified at approximately $9 and support near $7.50. A movement sustained above $8.76 could signal continued bullish trends, whereas a decline below $7.50 might suggest profit-taking or potential consolidation.

In conjunction with this market activity, Apollomics has announced a significant partnership with LaunXP International Co., Ltd. to facilitate the development and commercialization of vebreltinib, a proprietary c-Met inhibitor. This collaboration aims to enhance treatment options for non-small cell lung cancer (NSCLC) in specific Asian regions. As part of the agreement, Apollomics will receive an upfront payment of $10 million, along with the potential for an additional $50 million in pre-commercial milestones and royalties on net product sales.

Dr. Guo-Liang Yu, CEO of Apollomics, expressed enthusiasm regarding the partnership, stating that the collaboration aligns with their vision for maximizing vebreltinib’s potential. The combination of this innovative therapy with existing EGFR inhibitors is anticipated to redefine standard treatment protocols for NSCLC, an area in urgent need of effective therapies.

Supporting this initiative, Dr. Chiu-Heng Chen, Chairman and President of LaunXP, highlighted the significant preclinical data demonstrating vebreltinib’s effectiveness against drug-resistant mutations. The ongoing clinical trials aim to cement this combination therapy’s place in advancing cancer treatment, reflecting Apollomics’ broader commitment to providing impactful solutions for patients battling cancer.

Related news for (APLM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.